Literature DB >> 2521534

Age and dose related alteration of in vitro mixed lymphocyte culture response of blood lymphocytes from A-bomb survivors.

M Akiyama1, O L Zhou, Y Kusunoki, S Kyoizumi, N Kohno, S Akiba, R R Delongchamp.   

Abstract

The responsiveness of peripheral blood lymphocytes to allogenic antigens in mixed lymphocyte culture (MLC) was measured in 139 atomic-bomb survivors. The study revealed a significant decrease in MLC response with increasing dose of previous radiation exposure. This decline was marked in the survivors who were older than 15 at the time of the bomb (ATB). The results suggest a possible relationship between the recovery of T-cell-related function and the thymic function which processes mature T cells for the immune system. Thus it may be that in the advanced age ATB group, the thymus function had started to involute, allowing less recovery of T-cell function compared to young survivors who had adequate processing T-cell activity.

Entities:  

Mesh:

Year:  1989        PMID: 2521534

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  3 in total

Review 1.  Immunodeficiency of aging.

Authors:  E A Burns; J S Goodwin
Journal:  Drugs Aging       Date:  1997-11       Impact factor: 4.271

2.  Regulatory T cells in γ irradiation-induced immune suppression.

Authors:  Hugh I McFarland; Montserrat Puig; Lucja T Grajkowska; Kazuhide Tsuji; Jay P Lee; Karen P Mason; Daniela Verthelyi; Amy S Rosenberg
Journal:  PLoS One       Date:  2012-06-19       Impact factor: 3.240

3.  Long term effects of radiation exposure on telomere lengths of leukocytes and its associated biomarkers among atomic-bomb survivors.

Authors:  Ana Lustig; Ivo Shterev; Susan Geyer; Alvin Shi; Yiqun Hu; Yukari Morishita; Hiroko Nagamura; Keiko Sasaki; Mayumi Maki; Ikue Hayashi; Kyoji Furukawa; Kengo Yoshida; Junko Kajimura; Seishi Kyoizumi; Yoichiro Kusunoki; Waka Ohishi; Kei Nakachi; Nan-Ping Weng; Tomonori Hayashi
Journal:  Oncotarget       Date:  2016-06-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.